Body Clock May Personalise Depression Treatment

Researchers measured sleep duration, sleep onset latency, and daytime alertness in a cohort of depressed patients

A new study explores how circadian rhythm disruptions in depressed patients could predict which antidepressants will work best. Researchers found that sleep-wake patterns vary widely among individuals with depression. These differences may serve as biomarkers for treatment selection. The research focuses on how the body clock, or circadian system, interacts with mood regulation. People with depression often experience prolonged sleep yet still feel exhausted upon waking. Others lie awake at night despite wanting to rest. These irregularities are not just symptoms; they may reveal underlying biological differences. Why Sleep Patterns Predict Drug Response Antidepressants do not work equally well for everyone. Some patients respond quickly, while others need weeks or months to see improvement. The study suggests that timing of medication relative to the body clock could enhance effectiveness. For example, taking a drug at a specific time of day might align with peak receptor sensitivity.

Researchers measured sleep duration, sleep onset latency, and daytime alertness in a cohort of depressed patients. They then correlated these metrics with treatment outcomes. Patients with more severe circadian disruption showed different response rates to standard antidepressants. Can Timing Change Treatment Outcomes? The findings point toward a personalised approach. Instead of a one-size-fits-all prescription, clinicians could match medication to an individual's sleep profile. This could reduce trial-and-error prescribing. If validated, the method could shorten the time to symptom relief. It could also lower the risk of switching medications unnecessarily. Frequently Asked Questions Does this mean everyone with depression has a broken body clock? Not necessarily. The study identified patterns, not a universal defect. Some patients show mild disruption, others severe. The degree of disruption may correlate with drug response. How soon could this be used in clinics? The research is in the study phase.

Clinical trials would be needed before routine use. Experts estimate several years for integration into standard practice.